Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis
Source abstract
Abstract
Multiple sclerosis (MS) is a neuroimmunological disorder which causes axonal damage, demyelination and paralysis. Although numerous therapeutics have been developed for the effective treatment of MS and a few have been approved in recent decades, complete remission and treatment of MS remain a matter of concern. Nanotechnology is a potential approach for manipulating the properties of materials at the molecular level to attain desired properties. This approach is effective in the treatment of several CNS disorders by enhancing drug delivery, bioavailability and efficacy. We have briefly discussed the neuroimmunological disorders with a particular emphasis on MS. We also explored nanoengineered drug delivery systems, describing several nano-formulations for the treatment of MS, challenges and future of nanotechnology.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Multiple Sclerosis Research Studies · RNA Interference and Gene Delivery · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Morimoto K, Nakajima K. Role of the immune system in the development of the central nervous system. Front Neurosci. 2019;13:916. https://doi.org/10.3389/fnins.2019.00916.10.3389/fnins.2019.00916 ↗
2. Dantzer R. Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiol Rev. 2018;98(1):477–504. https://doi.org/10.1152/physrev.00039.2016.10.1152/physrev.00039.2016 ↗
3. da Silva APB, Silva RBM, Goi LDS, Molina RD, Machado DC, Sato DK. Experimental models of neuroimmunological disorders: a review. Front Neurol. 2020;11:389. https://doi.org/10.3389/fneur.2020.00389.10.3389/fneur.2020.00389 ↗
4. Nutma E, Willison H, Martino G, Amor S. Neuroimmunology - the past, present and future. Clin Exp Immunol. 2019;197(3):278–93. https://doi.org/10.1111/cei.13279.10.1111/cei.13279 ↗
5. O’Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J Clin Immunol. 2001;21(2):81–92. https://doi.org/10.1023/a:1011064007686.10.1023/a:1011064007686 ↗
6. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27–40. https://doi.org/10.1111/ene.13819.10.1111/ene.13819 ↗
7. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-1390.e1382. https://doi.org/10.1016/j.amjmed.2020.05.049.10.1016/j.amjmed.2020.05.049 ↗
8. Khambhla E, Shah V, Baviskar K. Drug delivery to CNS: challenges and opportunities with emphasis on biomaterials based drug delivery strategies. Curr Pharm Des. 2016;22(19):2913–22. https://doi.org/10.2174/1381612822666160401145951.10.2174/1381612822666160401145951 ↗
9. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184–91. https://doi.org/10.1001/jamaneurol.2019.3365.10.1001/jamaneurol.2019.3365 ↗
10. Gosselet F, Loiola RA, Roig A, Rosell A, Culot M. Central nervous system delivery of molecules across the blood-brain barrier. Neurochem Int. 2021;144:104952. https://doi.org/10.1016/j.neuint.2020.104952.10.1016/j.neuint.2020.104952 ↗
11. Naqvi S, Panghal A, Flora SJS. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Front Neurosci. 2020;14:494. https://doi.org/10.3389/fnins.2020.00494.10.3389/fnins.2020.00494 ↗
12. Saeedi M, Eslamifar M, Khezri K, Dizaj SM. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother. 2019;111:666–75. https://doi.org/10.1016/j.biopha.2018.12.133.10.1016/j.biopha.2018.12.133 ↗
13. Chhabra R, Tosi G, Grabrucker AM. Emerging use of nanotechnology in the treatment of neurological disorders. Curr Pharm Des. 2015;21(22):3111–30. https://doi.org/10.2174/1381612821666150531164124.10.2174/1381612821666150531164124 ↗
14. Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev. 2008;60(11):1226–40. https://doi.org/10.1016/j.addr.2008.03.015.10.1016/j.addr.2008.03.015 ↗
15. Patel MM, Patel BM. Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs. 2017;31(2):109–33. https://doi.org/10.1007/s40263-016-0405-9.10.1007/s40263-016-0405-9 ↗
16. Damavandi AR, et al. Advances in nanotechnology versus stem cell therapy for the theranostics of multiple sclerosis disease. Appl Nanosci. 2023;13(6):4043–73. https://doi.org/10.1007/s13204-022-02698-x.10.1007/s13204-022-02698-x ↗
17. Lu W, Yao J, Zhu X, Qi Y. Nanomedicines: redefining traditional medicine. Biomed Pharmacother. 2021;134:111103. https://doi.org/10.1016/j.biopha.2020.111103.10.1016/j.biopha.2020.111103 ↗
18. Robinson AP, Zhang JZ, Titus HE, Karl M, Merzliakov M, Dorfman AR, Karlik S, Stewart MG, Watt RK, Facer BD, Facer JD, Christian ND, Ho KS, Hotchkin MT, Mortenson MG, Miller RH, Miller SD. Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis. Sci Rep. 2020;10(1):1936. https://doi.org/10.1038/s41598-020-58709-w.10.1038/s41598-020-58709-w ↗
19. Cifuentes-Rius A, Desai A, Yuen D, Johnston APR, Voelcker NH. Inducing immune tolerance with dendritic cell-targeting nanomedicines. Nat Nanotechnol. 2021;16(1):37–46. https://doi.org/10.1038/s41565-020-00810-2.10.1038/s41565-020-00810-2 ↗
20. Nakanishi M, Furuno T. Molecular basis of neuroimmune interaction in an in vitro coculture approach. Cell Mol Immunol. 2008;5(4):249–59. https://doi.org/10.1038/cmi.2008.31.10.1038/cmi.2008.31 ↗
21. Marsland P, Parrella A, Orlofsky M, Lovelock DF, Vore AS, Varlinskaya EI, Deak T. Neuroendocrine and neuroimmune responses in male and female rats: evidence for functional immaturity of the neuroimmune system during early adolescence. Eur J Neurosci. 2022;55(9–10):2311–25. https://doi.org/10.1111/ejn.15118.10.1111/ejn.15118 ↗
22. Pascual M, Pla A, Miñarro J, Guerri C. Neuroimmune activation and myelin changes in adolescent rats exposed to high-dose alcohol and associated cognitive dysfunction: a review with reference to human adolescent drinking. Alcohol Alcohol. 2014;49(2):187–92. https://doi.org/10.1093/alcalc/agt164.10.1093/alcalc/agt164 ↗
23. Shouman K, Benarroch EE. Peripheral neuroimmune interactions: selected review and some clinical implications. Clin Auton Res. 2021;31(4):477–89. https://doi.org/10.1007/s10286-021-00787-5.10.1007/s10286-021-00787-5 ↗
24. Tian L, Ma L, Kaarela T, Li Z. Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J Neuroinflammation. 2012;9:155. https://doi.org/10.1186/1742-2094-9-155.10.1186/1742-2094-9-155 ↗
25. Godinho-Silva C, Cardoso F, Veiga-Fernandes H. Neuro-immune cell units: a new paradigm in physiology. Annu Rev Immunol. 2019;37:19–46. https://doi.org/10.1146/annurev-immunol-042718-041812.10.1146/annurev-immunol-042718-041812 ↗
26. Passaro AP, Lebos AL, Yao Y, Stice SL. Immune response in neurological pathology: emerging role of central and peripheral immune crosstalk. Front Immunol. 2021;12:676621. https://doi.org/10.3389/fimmu.2021.676621.10.3389/fimmu.2021.676621 ↗
27. Ohja K, Gozal E, Fahnestock M, Cai L, Cai J, Freedman JH, Switala A, El-Baz A, Barnes GN. Neuroimmunologic and neurotrophic interactions in autism spectrum disorders: relationship to neuroinflammation. Neuromolecular Med. 2018;20(2):161–73. https://doi.org/10.1007/s12017-018-8488-8.10.1007/s12017-018-8488-8 ↗
28. Charabati M, Wheeler MA, Weiner HL, Quintana FJ. Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting. Cell. 2023;186(7):1309–27. https://doi.org/10.1016/j.cell.2023.03.008.10.1016/j.cell.2023.03.008 ↗
29. Greer JM, McCombe PA. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol. 2011;234(1–2):7–18. https://doi.org/10.1016/j.jneuroim.2011.03.003.10.1016/j.jneuroim.2011.03.003 ↗
30. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86. https://doi.org/10.1212/wnl.0000000000000560.10.1212/wnl.0000000000000560 ↗
31. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nat Rev Dis Primers. 2018;4(1):43. https://doi.org/10.1038/s41572-018-0041-4.10.1038/s41572-018-0041-4 ↗
32. Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742–68. https://doi.org/10.1016/j.neuron.2018.01.021.10.1016/j.neuron.2018.01.021 ↗
33. Li R, Patterson KR, Bar-Or A. Reassessing B cell contributions in multiple sclerosis. Nat Immunol. 2018;19(7):696–707. https://doi.org/10.1038/s41590-018-0135-x.10.1038/s41590-018-0135-x ↗
34. Greiner T, Kipp M. What guides peripheral immune cells into the central nervous system? Cells. 2021. https://doi.org/10.3390/cells10082041.10.3390/cells10082041 ↗
35. Yu W, He J, Cai X, Yu Z, Zou Z, Fan D. Neuroimmune crosstalk between the peripheral and the central immune system in amyotrophic lateral sclerosis. Front Aging Neurosci. 2022;14:890958. https://doi.org/10.3389/fnagi.2022.890958.10.3389/fnagi.2022.890958 ↗
36. Guerrero BL, Sicotte NL. Microglia in multiple sclerosis: friend or foe? Front Immunol. 2020;11:374. https://doi.org/10.3389/fimmu.2020.00374.10.3389/fimmu.2020.00374 ↗
37. Yang JH, Rempe T, Whitmire N, Dunn-Pirio A, Graves JS. Therapeutic advances in multiple sclerosis. Front Neurol. 2022;13:824926. https://doi.org/10.3389/fneur.2022.824926.10.3389/fneur.2022.824926 ↗
38. Racke MK. Challenges in developing new multiple sclerosis therapies. Ther Adv Neurol Disord. 2008;1(2):1–3. https://doi.org/10.1177/1756285608095831.10.1177/1756285608095831 ↗
39. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2020;267(12):3489–98. https://doi.org/10.1007/s00415-019-09395-w.10.1007/s00415-019-09395-w ↗
40. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand’Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175–87. https://doi.org/10.1001/jama.2018.20588.10.1001/jama.2018.20588 ↗
41. Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol. 2018;25(10):1262-e1110. https://doi.org/10.1111/ene.13692.10.1111/ene.13692 ↗
42. Rafiee Zadeh A, et al. Mechanism and adverse effects of multiple sclerosis drugs: a review article Part 2. Int J Physiol Pathophysiol Pharmacol. 2019;11(4):105–14.
43. Barcelos IP, Troxell RM, Graves JS. Mitochondrial dysfunction and multiple sclerosis. Biology (Basel). 2019. https://doi.org/10.3390/biology8020037.10.3390/biology8020037 ↗
44. Scolding NJ, Pasquini M, Reingold SC, Cohen JA. Cell-based therapeutic strategies for multiple sclerosis. Brain. 2017;140(11):2776–96. https://doi.org/10.1093/brain/awx154.10.1093/brain/awx154 ↗
45. Bourque J, Hawiger D. Current and future immunotherapies for multiple sclerosis. Mo Med. 2021;118(4):334–9.
46. Al-Khamis FA. The use of immune modulating drugs for the treatment of multiple sclerosis. Neurosciences. 2016;21(1):4–9. https://doi.org/10.17712/nsj.2016.1.20150252.10.17712/nsj.2016.1.20150252 ↗
47. Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83(1):13–26. https://doi.org/10.1002/ana.25119.10.1002/ana.25119 ↗
48. Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179–99. https://doi.org/10.1038/s41573-020-00092-2.10.1038/s41573-020-00092-2 ↗
49. Furlan A, et al. COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge. Frontiers Immunol. 2021. https://doi.org/10.3389/fimmu.2021.763412.10.3389/fimmu.2021.763412 ↗
50. Wu H, Chen C, Gu L, Li J, Yue Y, Lyu M, Cui Y, Zhang X, Liu Y, Zhu H, Liao X, Zhang T, Sun F, Hu W. B cell deficiency promotes the initiation and progression of lung cancer. Front Oncol. 2022;12:1006477. https://doi.org/10.3389/fonc.2022.1006477.10.3389/fonc.2022.1006477 ↗
51. Disanto G, Berlanga AJ, Handel AE, Para AE, Burrell AM, Fries A, Handunnetthi L, De Luca GC, Morahan JM. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis. 2010;2011: 932351. https://doi.org/10.4061/2011/932351.10.4061/2011/932351 ↗
52. Mirabella M, et al. Treatment challenges in multiple sclerosis – a continued role for glatiramer acetate? Front Neurol. 2022. https://doi.org/10.3389/fneur.2022.844873.10.3389/fneur.2022.844873 ↗
53. Sá MJ, et al. State of the art and future challenges in multiple sclerosis research and medical management: an insight into the 5th international porto congress of multiple sclerosis. Neurol Therapy. 2020;9(2):281–300. https://doi.org/10.1007/s40120-020-00202-7.10.1007/s40120-020-00202-7 ↗
54. Cree BAC, Hartung HP, Barnett M. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022;35(3):262–70. https://doi.org/10.1097/wco.0000000000001063.10.1097/wco.0000000000001063 ↗
55. McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton’s tyrosine kinase in the immune system and disease. Immunology. 2021;164(4):722–36. https://doi.org/10.1111/imm.13416.10.1111/imm.13416 ↗
56. Krämer J, Bar-Or A, Turner TJ, Wiendl H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol. 2023;19(5):289–304. https://doi.org/10.1038/s41582-023-00800-7.10.1038/s41582-023-00800-7 ↗
57. Schneider R, Oh J. Bruton’s tyrosine kinase inhibition in multiple sclerosis. Curr Neurol Neurosci Rep. 2022;22(11):721–34. https://doi.org/10.1007/s11910-022-01229-z.10.1007/s11910-022-01229-z ↗
58. Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2022;18(1):40–55. https://doi.org/10.1038/s41582-021-00581-x.10.1038/s41582-021-00581-x ↗
59. Villoslada P. Neuroprotective therapies for multiple sclerosis and other demyelinating diseases. Multiple Sclerosis Demyelinating Disorders. 2016;1(1):1. https://doi.org/10.1186/s40893-016-0004-0.10.1186/s40893-016-0004-0 ↗
60. Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the american society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(5):845–54. https://doi.org/10.1016/j.bbmt.2019.02.014.10.1016/j.bbmt.2019.02.014 ↗
61. Strazielle N, Ghersi-Egea JF. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm. 2013;10(5):1473–91. https://doi.org/10.1021/mp300518e.10.1021/mp300518e ↗
62. Sartaj A, et al. An insight to brain targeting utilizing polymeric nanoparticles: effective treatment modalities for neurological disorders and brain tumor. Front Bioeng Biotechnol. 2022. https://doi.org/10.3389/fbioe.2022.788128.10.3389/fbioe.2022.788128 ↗
63. Liu Y, Cheng W, Xin H, Liu R, Wang Q, Cai W, Peng X, Yang F, Xin H. Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. Cancer Nanotechnol. 2023;14(1):28. https://doi.org/10.1186/s12645-023-00174-x.10.1186/s12645-023-00174-x ↗
64. Ahamed J, et al. Recent advances in nanoparticle-based approaches for the treatment of brain tumors: opportunities and challenges. Eur Polymer J. 2023;193:112111. https://doi.org/10.1016/j.eurpolymj.2023.112111.10.1016/j.eurpolymj.2023.112111 ↗
65. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazú V, Borm P, Estrada G, Ntziachristos V, Razansky D. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol. 2010;7:3. https://doi.org/10.1186/1743-8977-7-3.10.1186/1743-8977-7-3 ↗
66. Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ. Nanocarriers for targeted drug delivery. J Drug Delivery Sci Technol. 2021;62:102426. https://doi.org/10.1016/j.jddst.2021.102426.10.1016/j.jddst.2021.102426 ↗
67. Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L. The blood–brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem Biophys Res Commun. 2010;394(4):871–6. https://doi.org/10.1016/j.bbrc.2010.03.006.10.1016/j.bbrc.2010.03.006 ↗
68. He W, Kapate N, Shields CWt, Mitragotri S. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv Drug Deliv Rev. 2020;165–166:15–40. https://doi.org/10.1016/j.addr.2019.12.001.10.1016/j.addr.2019.12.001 ↗
69. Ghalamfarsa G, Hojjat-Farsangi M, Mohammadnia-Afrouzi M, Anvari E, Farhadi S, Yousefi M, Jadidi-Niaragh F. Application of nanomedicine for crossing the blood-brain barrier: theranostic opportunities in multiple sclerosis. J Immunotoxicol. 2016;13(5):603–19. https://doi.org/10.3109/1547691x.2016.1159264.10.3109/1547691x.2016.1159264 ↗
70. Park J, Choi SW, Cha BG, Kim J, Kang SJ. Alternative activation of macrophages through interleukin-13-loaded extra-large-pore mesoporous silica nanoparticles suppresses experimental autoimmune encephalomyelitis. ACS Biomater Sci Eng. 2021;7(9):4446–53. https://doi.org/10.1021/acsbiomaterials.1c00946.10.1021/acsbiomaterials.1c00946 ↗
71. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545–61. https://doi.org/10.1039/c2cs15327k.10.1039/c2cs15327k ↗
72. Cappellano G, Woldetsadik AD, Orilieri E, Shivakumar Y, Rizzi M, Carniato F, Gigliotti CL, Boggio E, Clemente N, Comi C, Dianzani C, Boldorini R, Chiocchetti A, Renò F, Dianzani U. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine. 2014;32(43):5681–9. https://doi.org/10.1016/j.vaccine.2014.08.016.10.1016/j.vaccine.2014.08.016 ↗
73. Pearson RM, Casey LM, Hughes KR, Wang LZ, North MG, Getts DR, Miller SD, Shea LD. Controlled delivery of single or multiple antigens in tolerogenic nanoparticles using peptide-polymer bioconjugates. Mol Ther. 2017;25(7):1655–64. https://doi.org/10.1016/j.ymthe.2017.04.015.10.1016/j.ymthe.2017.04.015 ↗
74. Meola A, Rao J, Chaudhary N, Sharma M, Chang SD. Gold nanoparticles for brain tumor imaging: a systematic review. Front Neurol. 2018;9:328. https://doi.org/10.3389/fneur.2018.00328.10.3389/fneur.2018.00328 ↗
75. Odularu AT. Metal nanoparticles: thermal decomposition, biomedicinal applications to cancer treatment, and future perspectives. Bioinorg Chem Appl. 2018;2018:9354708. https://doi.org/10.1155/2018/9354708.10.1155/2018/9354708 ↗
76. Malik MA, Wani MY, Hashim MA. Microemulsion method: A novel route to synthesize organic and inorganic nanomaterials: 1st Nano Update. Ar J Chem. 2012;5(4):397–417. https://doi.org/10.1016/j.arabjc.2010.09.027.10.1016/j.arabjc.2010.09.027 ↗
77. Shen J, Shafiq M, Ma M, Chen H. Synthesis and surface engineering of inorganic nanomaterials based on microfluidic technology. Nanomaterials (Basel). 2020. https://doi.org/10.3390/nano10061177.10.3390/nano10061177 ↗
78. Agrawal M, et al. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. J Control Release. 2020;321:372–415. https://doi.org/10.1016/j.jconrel.2020.02.020.10.1016/j.jconrel.2020.02.020 ↗
79. Kumar P, Sharma G, Gupta V, Kaur R, Thakur K, Malik R, Kumar A, Kaushal N, Katare OP, Raza K. Oral delivery of methylthioadenosine to the brain employing solid lipid nanoparticles: pharmacokinetic, behavioral, and histopathological evidences. AAPS PharmSciTech. 2019;20(2):74. https://doi.org/10.1208/s12249-019-1296-0.10.1208/s12249-019-1296-0 ↗
80. Goldmann K, Ensminger SM, Spriewald BM. Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance. Clin Vaccine Immunol. 2012;19(11):1758–64. https://doi.org/10.1128/cvi.00186-12.10.1128/cvi.00186-12 ↗
81. Youssef AEH, Dief AE, El Azhary NM, Abdelmonsif DA, El-Fetiany OS. LINGO-1 siRNA nanoparticles promote central remyelination in ethidium bromide-induced demyelination in rats. J Physiol Biochem. 2019;75(1):89–99. https://doi.org/10.1007/s13105-018-00660-6.10.1007/s13105-018-00660-6 ↗
82. González LF, Acuña E, Arellano G, Morales P, Sotomayor P, Oyarzun-Ampuero F, Naves R. Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: a promising simple, effective, non-invasive, and low-cost therapy. J Control Release. 2021;331:443–59. https://doi.org/10.1016/j.jconrel.2020.11.019.10.1016/j.jconrel.2020.11.019 ↗
83. Abbasi H, Kouchak M, Mirveis Z, Hajipour F, Khodarahmi M, Rahbar N, Handali S. What we need to know about liposomes as drug nanocarriers: an updated review. Adv Pharm Bull. 2023;13(1):7–23. https://doi.org/10.34172/apb.2023.009.10.34172/apb.2023.009 ↗
84. Liu P, Chen G, Zhang J. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives. Molecules. 2022;27(4):1372.10.3390/molecules27041372 ↗
85. Jebali A, Noroozi Karimabad M, Ahmadi Z, Khorramdel H, Kaeidi A, Mirzaei M, Zare-Bidaki M, Ahmadinia H, Vakilian A, Darekordi A, Hassanshahi G. Attenuation of inflammatory response in the EAE model by PEGlated nanoliposome of pistachio oils. J Neuroimmunol. 2020;347:577352. https://doi.org/10.1016/j.jneuroim.2020.577352.10.1016/j.jneuroim.2020.577352 ↗
86. Avnir Y, Turjeman K, Tulchinsky D, Sigal A, Kizelsztein P, Tzemach D, Gabizon A, Barenholz Y. Fabrication principles and their contribution to the superior in vivo therapeutic efficacy of nano-liposomes remote loaded with glucocorticoids. PLoS ONE. 2011;6(10):e25721. https://doi.org/10.1371/journal.pone.0025721.10.1371/journal.pone.0025721 ↗
87. Shimizu K, Agata K, Takasugi S, Goto S, Narita Y, Asai T, Magata Y, Oku N. New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect. J Control Release. 2021;335:389–97. https://doi.org/10.1016/j.jconrel.2021.05.027.10.1016/j.jconrel.2021.05.027 ↗
88. Juhairiyah F, de Lange ECM. Understanding drug delivery to the brain using liposome-based strategies: studies that provide mechanistic insights are essential. Aaps j. 2021;23(6):114. https://doi.org/10.1208/s12248-021-00648-z.10.1208/s12248-021-00648-z ↗
89. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain. 2003;126(Pt 8):1895–904. https://doi.org/10.1093/brain/awg176.10.1093/brain/awg176 ↗
90. Gaillard PJ, Appeldoorn CC, Rip J, Dorland R, van der Pol SM, Kooij G, de Vries HE, Reijerkerk A. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J Control Release. 2012;164(3):364–9. https://doi.org/10.1016/j.jconrel.2012.06.022.10.1016/j.jconrel.2012.06.022 ↗
91. Pujol-Autonell I, Mansilla MJ, Rodriguez-Fernandez S, Cano-Sarabia M, Navarro-Barriuso J, Ampudia RM, Rius A, Garcia-Jimeno S, Perna-Barrull D, Martinez-Caceres E, Maspoch D, Vives-Pi M. Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis. Nanomedicine (Lond). 2017;12(11):1231–42. https://doi.org/10.2217/nnm-2016-0410.10.2217/nnm-2016-0410 ↗
92. Kuperkar K, Patel D, Atanase LI, Bahadur P. Amphiphilic block copolymers: their structures, and self-assembly to polymeric micelles and polymersomes as drug delivery vehicles. Polymers (Basel). 2022. https://doi.org/10.3390/polym14214702.10.3390/polym14214702 ↗
93. Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. Adv Drug Deliv Rev. 2020;156:80–118. https://doi.org/10.1016/j.addr.2020.09.009.10.1016/j.addr.2020.09.009 ↗
94. Binyamin O, Larush L, Frid K, Keller G, Friedman-Levi Y, Ovadia H, Abramsky O, Magdassi S, Gabizon R. Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant. Int J Nanomedicine. 2015;10:7165–74. https://doi.org/10.2147/ijn.S92704.10.2147/ijn.S92704 ↗
95. Dolati S, Ahmadi M, Aghebti-Maleki L, Nikmaram A, Marofi F, Rikhtegar R, Ayromlou H, Yousefi M. Nanocurcumin is a potential novel therapy for multiple sclerosis by influencing inflammatory mediators. Pharmacol Rep. 2018;70(6):1158–67. https://doi.org/10.1016/j.pharep.2018.05.008.10.1016/j.pharep.2018.05.008 ↗
96. Garello F, Pagoto A, Arena F, Buffo A, Blasi F, Alberti D, Terreno E. MRI visualization of neuroinflammation using VCAM-1 targeted paramagnetic micelles. Nanomedicine. 2018;14(7):2341–50. https://doi.org/10.1016/j.nano.2017.10.002.10.1016/j.nano.2017.10.002 ↗
97. Tomalia DA, Christensen JB, Boas U. Dendrimers, Dendrons, and Dendritic Polymers: Discovery, Applications, and the Future. Cambridge University Press; 2012.10.1017/CBO9781139048859 ↗
98. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov Today. 2010;15(5–6):171–85. https://doi.org/10.1016/j.drudis.2010.01.009.10.1016/j.drudis.2010.01.009 ↗
99. Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B, Dolatabadi JEN, Hamblin MR. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018;12:177–90. https://doi.org/10.1016/j.apmt.2018.05.002.10.1016/j.apmt.2018.05.002 ↗
100. Cerqueira SR, Silva BL, Oliveira JM, Mano JF, Sousa N, Salgado AJ, Reis RL. Multifunctionalized CMCht/PAMAM dendrimer nanoparticles modulate the cellular uptake by astrocytes and oligodendrocytes in primary cultures of glial cells. Macromol Biosci. 2012;12(5):591–7. https://doi.org/10.1002/mabi.201100294.10.1002/mabi.201100294 ↗